Nombre del producto:1-(3,4-Dimethoxyphenyl)ethanone

IUPAC Name:1-(3,4-dimethoxyphenyl)ethan-1-one

CAS:1131-62-0
Fórmula molecular:C10H12O3
Pureza:98%
Número de catálogo:CM247812
Peso molecular:180.2

Unidad de embalaje Stock disponible Precio($) Cantidad
CM247812-500g in stock ƤDz

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1131-62-0
Fórmula molecular:C10H12O3
Punto de fusión:-
Código de sonrisas:CC(C1=CC=C(OC)C(OC)=C1)=O
Densidad:
Número de catálogo:CM247812
Peso molecular:180.2
Punto de ebullición:287°C at 760 mmHg
Nº Mdl:MFCD00008737
Almacenamiento:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Cabozantinib
On August 21, 2023, Exelixis and Ipsen announced that the global phase 3 CONTACT-02 study of cabozantinib (Cabometyx ®) in combination with atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) met the primary endpoint of progression-free survival (PFS) in an interim analysis.
Prostate cancer is the fourth most common cancer worldwide and the second most common cancer among men. At present, the drugs approved for the treatment of CRPC are basically AR inhibitors or PARP inhibitors, and the combination therapy of Cabozantinib + Atezolizumab is expected to become a new treatment option for such patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.